Examining recommendations for the use of biologics and other systemic therapies during COVID-19: a review and comparison of available dermatology guidelines and patient registries
Background The novel coronavirus (COVID-19) has an affinity for almost every organ system, including the skin. This review article will compile and compare dermatology guidelines related to the dermatologic care of patients during the COVID-19 pandemic. Objective To review and compare the available...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-04-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09546634.2020.1808154 |
| _version_ | 1797683549982162944 |
|---|---|
| author | Mary Beth Gadarowski Esther A. Balogh Arjun M. Bashyam Steven R. Feldman |
| author_facet | Mary Beth Gadarowski Esther A. Balogh Arjun M. Bashyam Steven R. Feldman |
| author_sort | Mary Beth Gadarowski |
| collection | DOAJ |
| description | Background The novel coronavirus (COVID-19) has an affinity for almost every organ system, including the skin. This review article will compile and compare dermatology guidelines related to the dermatologic care of patients during the COVID-19 pandemic. Objective To review and compare the available guidelines and recommendations on use of biologics and other systemic therapies in dermatology patients. Methods We conducted a search for guidelines and recommendations for dermatology providers, with specific attention to the management of biologics and non-biologic systemic agents during COVID-19. International and United States-based guidelines specific to the field of dermatology and guidance for healthcare providers were used as inclusion criteria. Available registries were included as well. Conclusion The guidelines stress a shared decision-making approach with risk-benefit analysis and treatment strategy modifications tailored to each unique patient case. The guidelines were all concordant with one another in highlighting the importance that patients should not discontinue their medications without first speaking with their providers. |
| first_indexed | 2024-03-12T00:15:46Z |
| format | Article |
| id | doaj.art-315a4c2739c94f4aadc8ac20b5ea5b66 |
| institution | Directory Open Access Journal |
| issn | 0954-6634 1471-1753 |
| language | English |
| last_indexed | 2024-03-12T00:15:46Z |
| publishDate | 2022-04-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj.art-315a4c2739c94f4aadc8ac20b5ea5b662023-09-15T14:28:49ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532022-04-013331208121210.1080/09546634.2020.18081541808154Examining recommendations for the use of biologics and other systemic therapies during COVID-19: a review and comparison of available dermatology guidelines and patient registriesMary Beth Gadarowski0Esther A. Balogh1Arjun M. Bashyam2Steven R. Feldman3Center for Dermatology Research, Department of Dermatology, Wake Forest School of MedicineCenter for Dermatology Research, Department of Dermatology, Wake Forest School of MedicineCenter for Dermatology Research, Department of Dermatology, Wake Forest School of MedicineCenter for Dermatology Research, Department of Dermatology, Wake Forest School of MedicineBackground The novel coronavirus (COVID-19) has an affinity for almost every organ system, including the skin. This review article will compile and compare dermatology guidelines related to the dermatologic care of patients during the COVID-19 pandemic. Objective To review and compare the available guidelines and recommendations on use of biologics and other systemic therapies in dermatology patients. Methods We conducted a search for guidelines and recommendations for dermatology providers, with specific attention to the management of biologics and non-biologic systemic agents during COVID-19. International and United States-based guidelines specific to the field of dermatology and guidance for healthcare providers were used as inclusion criteria. Available registries were included as well. Conclusion The guidelines stress a shared decision-making approach with risk-benefit analysis and treatment strategy modifications tailored to each unique patient case. The guidelines were all concordant with one another in highlighting the importance that patients should not discontinue their medications without first speaking with their providers.http://dx.doi.org/10.1080/09546634.2020.1808154covid-19coronavirusguidelinebiologic therapynon-biologic systemicregistry |
| spellingShingle | Mary Beth Gadarowski Esther A. Balogh Arjun M. Bashyam Steven R. Feldman Examining recommendations for the use of biologics and other systemic therapies during COVID-19: a review and comparison of available dermatology guidelines and patient registries Journal of Dermatological Treatment covid-19 coronavirus guideline biologic therapy non-biologic systemic registry |
| title | Examining recommendations for the use of biologics and other systemic therapies during COVID-19: a review and comparison of available dermatology guidelines and patient registries |
| title_full | Examining recommendations for the use of biologics and other systemic therapies during COVID-19: a review and comparison of available dermatology guidelines and patient registries |
| title_fullStr | Examining recommendations for the use of biologics and other systemic therapies during COVID-19: a review and comparison of available dermatology guidelines and patient registries |
| title_full_unstemmed | Examining recommendations for the use of biologics and other systemic therapies during COVID-19: a review and comparison of available dermatology guidelines and patient registries |
| title_short | Examining recommendations for the use of biologics and other systemic therapies during COVID-19: a review and comparison of available dermatology guidelines and patient registries |
| title_sort | examining recommendations for the use of biologics and other systemic therapies during covid 19 a review and comparison of available dermatology guidelines and patient registries |
| topic | covid-19 coronavirus guideline biologic therapy non-biologic systemic registry |
| url | http://dx.doi.org/10.1080/09546634.2020.1808154 |
| work_keys_str_mv | AT marybethgadarowski examiningrecommendationsfortheuseofbiologicsandothersystemictherapiesduringcovid19areviewandcomparisonofavailabledermatologyguidelinesandpatientregistries AT estherabalogh examiningrecommendationsfortheuseofbiologicsandothersystemictherapiesduringcovid19areviewandcomparisonofavailabledermatologyguidelinesandpatientregistries AT arjunmbashyam examiningrecommendationsfortheuseofbiologicsandothersystemictherapiesduringcovid19areviewandcomparisonofavailabledermatologyguidelinesandpatientregistries AT stevenrfeldman examiningrecommendationsfortheuseofbiologicsandothersystemictherapiesduringcovid19areviewandcomparisonofavailabledermatologyguidelinesandpatientregistries |